Keytruda

After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market
After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market
Endpoints
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
anti-PD-L1
Flag link:
Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
CP Wire
Merck
Keytruda
melanoma
China
Flag link:
Keytruda Becomes the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Merck
Keytruda
melanoma
Flag link:
Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Endpoints
Merck
Keytruda
clinical trials
squamous cell carcinoma of the head and neck
Flag link:
Is Roche's latest Tecentriq win really a win for Merck's Keytruda?
Is Roche's latest Tecentriq win really a win for Merck's Keytruda?
Fierce Pharma
Roche
immuno-oncology
Tecentriw
Merck
Keytruda
non-small cell lung cancer
Flag link:
FDA Limits the Use of Tecentriq and Keytruda
FDA Limits the Use of Tecentriq and Keytruda
RAPS.org
FDA
Roche
Merck
Tecentriq
Keytruda
metastatic urothelial cancer
Flag link:
FDA Grants Priority Review to Keytruda Combination Therapy for Metastatic Squamous Non-Small Cell Lung Cancer
FDA Grants Priority Review to Keytruda Combination Therapy for Metastatic Squamous Non-Small Cell Lung Cancer
CP Wire
Merck
Keytruda
non-small cell lung cancer
metastatic squamous non-small cell lung cancer
priority review
FDA
Flag link:
FDA Grants Priority Review to Keytruda Combination Therapy for Metastatic Squamous Non-Small Cell Lung Cancer
Merck
Keytruda
squamous cell non-small cell lung cancer
Flag link:
FDA limits first-line bladder cancer labels for Keytruda, Tecentriq
FDA limits first-line bladder cancer labels for Keytruda, Tecentriq
Biopharma Dive
FDA
Merck
Keytruda
Roche
Tecentriq
bladder cancer
Flag link:
Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain
Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain
Endpoints
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Flag link:
Merck's Keytruda snags I-O's first cervical cancer nod to back up HPV fighter Gardasil
Merck's Keytruda snags I-O's first cervical cancer nod to back up HPV fighter Gardasil
Fierce Pharma
Merck
Keytruda
FDA
cervical cancer
Flag link:
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Humira
AbbVie
Keytruda
Merck
Revlimid
Celgene
Opdivo
Bristol-Myers Squibb
Flag link:
ASCO18: 3 unanswered questions from oncology's largest conference
ASCO18: 3 unanswered questions from oncology's largest conference
Biopharma Dive
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
immunotherapy combinations
non-small cell lung cancer
Flag link:
ASCO: Merck and its new multibillion-dollar partners hone plans for marketing onslaught
ASCO: Merck and its new multibillion-dollar partners hone plans for marketing onslaught
Fierce Pharma
Merck
ASCO 2018
Keytruda
AstraZeneca
Eisai
Flag link:
More Good News For Keytruda - Shows Promising Results in Patients with Advanced Small Cell Lung Cancer
More Good News For Keytruda - Shows Promising Results in Patients with Advanced Small Cell Lung Cancer
CP Wire
Merck
Keytruda
small cell lung cancer
ASCO 2018
Flag link:
More Good News For Keytruda - Shows Promising Results in Patients with Advanced Small Cell Lung Cancer
Merck
Keytruda
small cell lung cancer
Flag link:
First Major Trial Of Keytruda For Prostate Cancer Shows It Works, But Only For A Minority Of Men
First Major Trial Of Keytruda For Prostate Cancer Shows It Works, But Only For A Minority Of Men
Forbes
Merck
Keytruda
advanced prostate cancer
ASCO 2018
Flag link:
Merck's Keytruda shown to extend lung cancer survival in two trials
Merck's Keytruda shown to extend lung cancer survival in two trials
Reuters
Merck
Keytruda
advanced squamous non-small cell lung cancer
ASCO 2018
Flag link:
Ahead of ASCO, BMS' Opdivo leads Merck's Keytruda in U.S. sales—but not for long, analyst predicts
Ahead of ASCO, BMS' Opdivo leads Merck's Keytruda in U.S. sales—but not for long, analyst predicts
Fierce Pharma
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Flag link:
5 Best-Selling Orphan Drugs in the U.S.
5 Best-Selling Orphan Drugs in the U.S.
Motley Fool
orphan drugs
Celgene
Revlimid
Roche
Rituxan
Teva Pharmaceutical
Copaxone
Opdivo
Bristol-Myers Squibb
Merck
Keytruda
Flag link:

Pages